From 1 May, classical Hodgkin’s lymphoma patients will no longer pay over $200,000 per course of treatment, now only paying a maximum of $39.50 per script, with concessional patients–including pensioners–paying just $6.40.
Member for Gilmore, Ann Sudmalis said, “More than 120 Australians with classical Hodgkin’s lymphoma will now access Keytruda each year at a drastically reduced cost.”
“This listing provides a new option for patients that cannot undergo, or have no response from, the normal chemotherapy treatment.
“Also on May 1, we will make other medicines available to treat a range of conditions, including non-small cell lung cancer, epilepsy and ulcerative colitis,” said Mrs Sudmalis.
Full details are available at www.annsudmalismp.com.au
